Can-Fite BioPharma Ltd. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (26)

Latest Posts

About This Stock More About This Stock
Week In Review: Shanghai Junshi Biosciences Files For $500 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, August 11, 2018 7:27 PM EDT
Shanghai Junshi Biosciences has filed for a Hong Kong IPO that is expected to raise up to $500 million. Junshi is developing a pipeline of 13 biologic drugs, including immuno-oncology treatments.
In this article: SGYP, CELG, GILD, CANF, BGNE
Read
Biotech Digest – JAZZ Reports Positive Results, CTSO Inks New Contract, AMGN Forges Collaboration
Article By: KKD Healthcare Analytics
Tuesday, April 25, 2017 10:15 AM EDT
Capricor Therapeutics announced encouraging six-month results in a Phase 1/2 clinical trial. Jazz Pharmaceuticals reported results from its Phase 2/3 clinical trial. Amgen announced its new collaboration with Novartis.
In this article: NVS, EAPH, ACHN, JAZZ, AMGN, CANF, CAPR, CTSO
Read
Can-Fite Gearing-Up For Phase 2 NASH Program
Article By: Jason Napodano
Wednesday, March 1, 2017 1:50 PM EDT
Can-Fite's entire market capitalization is only $33 million and I have to believe that the majority of that value is Phase 3 piclidenoson for the treatment of rheumatoid arthritis and psoriasis.
In this article: CANF
Read
CanFite's Piclidenoson Positioned For Successful Phase 3 In Psoriasis
Article By: Jason Napodano
Wednesday, November 2, 2016 3:01 PM EDT
Can-Fite BioPharma Ltd. announced that the company reached an agreement with the European Medicines Agency on the final design of a global pivotal Phase 3 trial for its lead drug candidate, piclidenoson, in the treatment of psoriasis.
In this article: CANF
Read
Can-Fite An Emerging NASH Play With CF102
Article By: Jason Napodano
Thursday, October 13, 2016 9:10 AM EDT
On October 13, 2016, Can-Fite Biopharma Ltd (CANF) announced it has submitted the clinical trial protocol for its Phase II study of CF102 in the treatment of NAFLD, the precursor to NASH, to a leading Institutional Review Board (IRB) in Israel.
In this article: CANF Also: AGN, GILD, ICPT
Read

PARTNER HEADLINES

Latest Tweets for $CANF

No tweets yet!